Spotlight On... Langer drug delivering biopolymer maker raises $25M; Moberg Pharma making progress on lozenge formulation painkiller; and more...

Paris' Gecko Biomedical has raised $25 million in support of its drug-delivering biopolymer platform for tissue reconstruction. Co-financed by MIT's Robert Langer, the company is aiming to earn its first approval within a year, for a cardiovascular reconstruction candidate. More from FierceMedicalDevices

> Sweden's Moberg Pharma said it would begin Phase III trials of its patent pending lozenge formulation of bupivacaine for pain management in oral mucositis among cancer patients. Cadila Pharmaceuticals will conduct a Phase III trial in its home country of India in return for exclusive rights commercialization rights in India and Africa, with the exception of South Africa. More | More

> A study in the journal Optical Materials Express has found that porous gold nanodisks can kill bacteria quickly. "We showed that all of the bacteria were killed pretty quickly … within 5 to 25 seconds. That's a very fast process," said corresponding author Wei-Chuan Shih, professor of electrical and computer engineering department at the University of Houston. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.